Histological growth patterns and genotype in oligodendroglial tumours: Correlation with MRI features

Brain

Volumn 129, Issue 7, 2006, Pages 1884-1891

  Jenkinson, Michael D ^a,b,e   Du Plessis, Daniel G ^b,c   Smith, Trevor S ^a   Joyce, Kathy A ^d   Warnke, Peter C ^a,b   Walker, Carol ^d  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d CLATTERBRIDGE HOSPITAL   (United Kingdom)

^e Clinical Science Centre   (United Kingdom)

Author keywords

Brain tumour; Histopathology; Molecular genetics; MRI

Indexed keywords

ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER INFILTRATION; CELL TYPE; CONTRAST ENHANCEMENT; CORRELATION COEFFICIENT; FEMALE; GENOTYPE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAGNETISM; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIAL TUMOR; PRIORITY JOURNAL; SIGNAL DETECTION; SOLID TUMOR; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; ALLELIC IMBALANCE; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA;

EID: 33745699805     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl108     Document Type: Article

References (32)

1. Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer 1987; 60: 1519-31.
2. Batzdorf U, Malamud N. The problem of multicentric gliomas. J Neurosurg 1963; 20: 122-36.
3. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000; 48: 825-30.
4. Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro-oncology 1999; 1: 52-60.
5. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-4.
6. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
7. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol 1997a; 34: 61-78.
8. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 1997b; 34: 37-59.
9. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002; 58: 111-7; discussion 117.
10. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003; 60: 443-56.
11. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004; 63: 314-22.
12. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004; 14: 121-30.
13. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-36.
14. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-45.
15. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004; 70: 161-81.
16. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62: 450-9.
17. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 2003; 15: 197-203.
18. Kleihues PC, Cavanee WK. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press; 2000.
19. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-5.
20. Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10: 4303-6.
21. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T, et al. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 2004; 14: 34-42.
22. Palfi S, Swanson KR, De Bouard S, Chretien F, Oliveira R, Gherardi RK, et al. Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer 2004; 91: 745-52.
23. Perry A. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol 2001; 8: 183-99.
24. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-90.
25. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-45.
26. Tilgner J, Herr M, Ostertag C, Volk B. Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis - influence of clinical factors. Neurosurgery 2005; 56: 257-65.
27. van den Bent MJ. Diagnosis and management of oligodendroglioma. Semin Oncol 2004; 31: 645-52.
28. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97: 1276-84.
29. Walker C, Joyce KA, Thompson-Hehir J, Davies MP, Gibbs FE, Halliwell N, et al. Characterisation of molecular alterations in microdissected archival gliomas. Acta Neuropathol (Berl) 2001; 101: 321-33.
30. Walker C, du Plessis DG, Joyce KA, Machell Y, Thomson-Hehir J, Al Haddad SA, et al. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 2003; 9: 4841-51.
31. Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 2004; 10: 7182-91.
32. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 2005; 57: 855-65.